Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Irbesartan/Amlodipine FDC vs Co-administration
NCT05663073Phase 1Completed
- Sponsor
- Handok
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of irbesartan and amlodipine in hypertension (HTN) (2 arms), sponsored by Handok. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to Last Quantifiable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Sep 2022; status: completed.
02
Drugs
irbesartanamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05663073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663073.